每周股票复盘：千金药业（600479）并购获证监会注册批复

Group 1 - The stock price of Qianjin Pharmaceutical (600479) closed at 10.96 yuan on September 12, 2025, up 0.37% from the previous week [1] - The company's total market capitalization is 4.625 billion yuan, ranking 45th out of 67 in the traditional Chinese medicine sector and 3516th out of 5153 in the A-share market [1] - The highest intraday price reached 11.23 yuan and the lowest was 10.85 yuan on September 11, 2025 [1] Group 2 - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission (CSRC) for the issuance of shares to acquire assets, specifically 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [2] - The approval is valid for 12 months from the date of issuance, and the company must comply with the application documents submitted to the Shanghai Stock Exchange [2] - The company is required to fulfill information disclosure obligations and report any significant issues during the implementation process [2] Group 3 - The financial advisor, Guotai Junan Securities Co., Ltd., provided a continuous supervision opinion on the acquisition report, confirming that the acquirer and its concerted parties have complied with regulations [1][3] - There are no major adjustments planned for the acquirer's main business, asset restructuring, board or executive changes, employee hiring, dividend policies, or other significant plans during the supervision period [1][3]